Universal Risk Stratification in Stage I–III Cutaneous Melanoma Using 31‐gene Expression Profiling: A Single‐Center Study
Journal of Surgical Oncology · 2026-06 · 133 (7) · 889-900
DOI: 10.1002/jso.70229 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Surgical Oncology, online erschienen am 08.03.2026. Verfasst von Daniel B Gehle und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, University of Tennessee Health Science Center, Memphis, TN, USA. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms, Gene Expression Profiling, Neoplasm Recurrence, Local. Die Arbeit nennt 32 Literaturangaben.
Abstract (Originalsprache)
Background
Patients with early‐stage cutaneous melanoma (CM) have low individual risk but account for most distant recurrences. The utility of gene expression profiling (GEP) in CM risk stratification and clinical management remains unclear.
Methods
From 2015 to 2022, CM patients at a single center were universally referred for DecisionDx 31‐GEP. Patients with prior recurrence or not undergoing excision were excluded. The Kaplan–Meier method and Cox proportional hazards models were used to evaluate primary outcomes of recurrence‐free survival (RFS), distant metastasis‐free survival (DMFS), and melanoma‐specific survival (MSS). Secondary outcomes were sentinel lymph node biopsy (SLNB) positivity and recurrence subtype events.
Results
689 patients were analyzed: 63% GEP Class 1A, 16.1% Class 1B/2A, 16.1% Class 2B, and 4.8% unclassified. After staging, 86.6% were stage I/II and 13.4% stage III. Median follow‐up was 4.85 years. On multivariable analysis, GEP remained significantly predictive of RFS (Class 1B/2A HR = 4.022; Class 2B HR = 3.052), DMFS (Class 1B/2A HR = 4.403; Class 2B HR = 3.729), and MSS (Class 1B/2A HR = 6.656; Class 2B HR = 11.583) ( p < 0.05 for all). Older Class 1A patients with indication for SLNB had lower SLNB positivity (2.8% ≥ 65 years, 0% ≥ 75 years).
Conclusions
Our data show GEP remains a robust predictor of recurrence and MSS after adjusting for clinicopathologic factors overall but is not predictive for all outcomes in stage‐stratified analyses, particularly Stage II disease. Stage IA patients should forgo GEP altogether testing due to its futility in this population. Older patients with low‐risk GEP may be candidates for avoidance of SLNB given lower positivity rates. GEP Class 2B patients represent a relatively high‐risk population regardless of SLNB status.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, University of Tennessee Health Science Center, Memphis, TN, USA.
- Department of Surgery, St. Jude Children's Research Hospital, Memphis, TN, USA.
- College of Medicine, University of Tennessee Health Science Center, Memphis, TN, USA.
- Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis, TN, USA.
ORCID-Profile: Daniel B Gehle, Emme M Fitts, Chelsea R Olson, Andrew M Fleming, Feng Liu-Smith, Simonne S Nouer, Andrew J Murphy, Martin D Fleming
Zitieren
APA
Gehle, D. B., Morgan, P. W., Fitts, E. M., Hauser, N. L., Olson, C. R., Fleming, A. M., Freitas, J. P., Liu-Smith, F., Nouer, S. S., Murphy, A. J., & Fleming, M. D. (2026). Universal Risk Stratification in Stage I–III Cutaneous Melanoma Using 31‐gene Expression Profiling: A Single‐Center Study. Journal of Surgical Oncology, 133(7), 889-900. https://doi.org/10.1002/jso.70229
Vancouver
Gehle DB, Morgan PW, Fitts EM, Hauser NL, Olson CR, Fleming AM, et al. Universal Risk Stratification in Stage I–III Cutaneous Melanoma Using 31‐gene Expression Profiling: A Single‐Center Study. Journal of Surgical Oncology. 2026;133(7):889-900. doi:10.1002/jso.70229
BibTeX
@article{Gehle2026,
author = {Gehle, Daniel B and Morgan, Philip W and Fitts, Emme M and Hauser, Nathaniel L and Olson, Chelsea R and Fleming, Andrew M and Freitas, Julia Pedo and Liu-Smith, Feng and Nouer, Simonne S and Murphy, Andrew J and Fleming, Martin D},
title = {Universal Risk Stratification in Stage I–III Cutaneous Melanoma Using 31‐gene Expression Profiling: A Single‐Center Study},
journal = {Journal of Surgical Oncology},
year = {2026},
volume = {133},
number = {7},
pages = {889--900},
doi = {10.1002/jso.70229}
}
EUVIMED